NovoCure Statistics
Total Valuation
NovoCure has a market cap or net worth of $2.05 billion. The enterprise value is $1.77 billion.
| Market Cap | 2.05B |
| Enterprise Value | 1.77B |
Important Dates
The last earnings date was Thursday, July 25, 2024, before market open.
| Earnings Date | Jul 25, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
NovoCure has 107.61 million shares outstanding. The number of shares has increased by 1.33% in one year.
| Shares Outstanding | 107.61M |
| Shares Change (YoY) | +1.33% |
| Shares Change (QoQ) | +0.40% |
| Owned by Insiders (%) | 9.26% |
| Owned by Institutions (%) | 85.41% |
| Float | 98.45M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.72 |
| Forward PS | 3.56 |
| PB Ratio | 5.66 |
| P/FCF Ratio | n/a |
| PEG Ratio | -0.47 |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.21 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.46, with a Debt / Equity ratio of 1.87.
| Current Ratio | 6.46 |
| Quick Ratio | 6.22 |
| Debt / Equity | 1.87 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 4.21 |
Financial Efficiency
Return on equity (ROE) is -45.70% and return on invested capital (ROIC) is -17.85%.
| Return on Equity (ROE) | -45.70% |
| Return on Assets (ROA) | -14.60% |
| Return on Capital (ROIC) | -17.85% |
| Revenue Per Employee | $378,502 |
| Profits Per Employee | -$116,104 |
| Employee Count | 1,453 |
| Asset Turnover | 0.48 |
| Inventory Turnover | 3.62 |
Taxes
In the past 12 months, NovoCure has paid $27.57 million in taxes.
| Income Tax | 27.57M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -53.61% in the last 52 weeks. The beta is 0.69, so NovoCure's price volatility has been lower than the market average.
| Beta (5Y) | 0.69 |
| 52-Week Price Change | -53.61% |
| 50-Day Moving Average | 19.95 |
| 200-Day Moving Average | 15.50 |
| Relative Strength Index (RSI) | 51.85 |
| Average Volume (20 Days) | 1,912,982 |
Short Selling Information
The latest short interest is 7.02 million, so 6.52% of the outstanding shares have been sold short.
| Short Interest | 7.02M |
| Short Previous Month | 6.19M |
| Short % of Shares Out | 6.52% |
| Short % of Float | 7.13% |
| Short Ratio (days to cover) | 3.44 |
Income Statement
In the last 12 months, NovoCure had revenue of $549.96 million and -$168.70 million in losses. Loss per share was -$1.57.
| Revenue | 549.96M |
| Gross Profit | 416.97M |
| Operating Income | -185.06M |
| Pretax Income | -141.13M |
| Net Income | -168.70M |
| EBITDA | -173.86M |
| EBIT | -185.06M |
| Loss Per Share | -$1.57 |
Balance Sheet
The company has $954.83 million in cash and $675.20 million in debt, giving a net cash position of $279.63 million or $2.60 per share.
| Cash & Cash Equivalents | 954.83M |
| Total Debt | 675.20M |
| Net Cash | 279.63M |
| Net Cash Per Share | $2.60 |
| Equity (Book Value) | 361.75M |
| Book Value Per Share | 3.36 |
| Working Capital | 923.66M |
Cash Flow
In the last 12 months, operating cash flow was -$67.17 million and capital expenditures -$37.30 million, giving a free cash flow of -$104.47 million.
| Operating Cash Flow | -67.17M |
| Capital Expenditures | -37.30M |
| Free Cash Flow | -104.47M |
| FCF Per Share | -$0.97 |
Margins
Gross margin is 75.82%, with operating and profit margins of -33.65% and -30.67%.
| Gross Margin | 75.82% |
| Operating Margin | -33.65% |
| Pretax Margin | -25.66% |
| Profit Margin | -30.67% |
| EBITDA Margin | -31.61% |
| EBIT Margin | -33.65% |
| FCF Margin | -19.00% |
Dividends & Yields
NovoCure does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.33% |
| Shareholder Yield | -1.33% |
| Earnings Yield | -8.24% |
| FCF Yield | -5.10% |
Analyst Forecast
The average price target for NovoCure is $30.00, which is 57.73% higher than the current price. The consensus rating is "Buy".
| Price Target | $30.00 |
| Price Target Difference | 57.73% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 13.60% |
| EPS Growth Forecast (5Y) | -14.77% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
NovoCure has an Altman Z-Score of 1.09 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.09 |
| Piotroski F-Score | 2 |